Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131 ↗

Phase 2 Active not recruiting 15 enrolled Emory University Genentech, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.

Timeline

Start: 2019-06-05
Primary completion: 2022-09-27
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab and Hyaluronidase Human	Unknown	—	Intravenous
Background	Ipilimumab	Monoclonal antibody	—	—
Background	Nivolumab	Monoclonal antibody	—	—

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Summary

Timeline

Drugs

Indications